Handelsavisen
prelaunch
Companies ›Healthcare ›ALOPM.PA
AL
ALOPM.PA — Euronext Paris Biotechnology & Medical Research

Oncodesign Precision Medicine Opm SA

€0,31
Open in Charts → Attach watcher ⌖
— —
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Oncodesign Precision Medicine Opm SA provides healthcare diagnostics services, focusing on precision medicine solutions for oncology applications.

Business. Oncodesign Precision Medicine Opm SA (ALOPM.PA) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALOPM.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALOPM.PA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Oncodesign Precision Medicine Opm SA (ALOPM.PA) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED
    — missing data
    Key takeaways
    • Oncodesign Precision Medicine Opm SA has no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities.
    • The company's last actual revenue of 260,000 EUR is significantly below the mean revenue estimate of 101.8 million EUR, suggesting a substantial gap between current performance and analyst expectations.
    • Liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents, indicating potential financial instability or lack of transparency.
    • Analyst estimates suggest a 99.7% growth expectation for the company, but without historical revenue data or a clear path to scaling, this projection remains speculative.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2026-04-30
    FY 2026 · Full-year highlights

    Revenue €207.0k, −80,7% YoY; Operating income +21,3% YoY.

    Revenue€207.0k−80,7 % YoY
    Operating income-€7.8M+21,3 % YoY
    Net income-€7.2M+10,9 % YoY
    Free cash flow—
    EPS—
    Operating cash flow—
    Financials
    Income statement
    Revenue€207.0k
    Gross profit€218.5k
    Operating income-€7.8M
    Net income-€7.2M
    Margins
    Gross margin105.6%
    Operating margin-3776.8%
    Net margin-3482.2%
    FCF margin—
    Balance sheet
    Total assets€10.7M
    Total liabilities€11.1M
    Total equity-€429.4k
    Cash & equivalents—
    Long-term debt€7.6M
    P&L flow · revenue → net income
    Revenue €207.0kOperating costs €8.0MNet income €7.2M
    Highlights
    • ▍Revenue €207.0k, −80,7% YoY
    • ▍Operating income +21,3% YoY
    • ▍Net income +10,9% YoY
    • ▍Net margin -3482.2%

    Valuation FY

    Market price
    €0,31
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Operating income · consensus88,6M EUR
    Revenue surprise
    −99,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Oncodesign Precision Medicine Opm SA Market data — financials · 2026-05-27
    • Oncodesign Precision Medicine Opm SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALOPM.PACanonical
    Euronext Paris · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-04-30 20:40 UTCEARNINGSAnnual results — FY 2026 Revenue EUR 0.2M · Net EUR -7.2M
    2025-04-03 17:00 UTCEARNINGSAnnual results — FY 2025 Revenue EUR 1.1M · Net EUR -8.1M
    2024-04-25 19:47 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 8.0M · Net EUR -0.2M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage